Detailed Narrative
CF Label Expansions and Pipeline Progress
Vertex achieved significant label expansions for ALYFTREK and TRIKAFTA in the U.S., now covering patients with at least one responsive CFTR gene variant, extending eligibility to about 95% of people with CF. Submissions for younger age groups (ALYFTREK 2-5 years, TRIKAFTA 1-2 years) are planned soon. The next-generation 3.0 CFTR modulators (VX-828, VX-581, VX-272) are progressing, with VX-828 results expected in H2 2026, aiming to further improve upon existing treatments.
Renal Franchise Development and Pove's Profile
The renal franchise is rapidly establishing itself as Vertex's fourth, with four programs in mid- and late-stage development, including Pove in IgAN and primary membranous nephropathy, inaxaplin in AMKD, and VX-407 in ADPKD. Pove's potential best-in-class profile in IgAN stems from its engineered TACI fusion protein design, delivering optimal dual BAFF/APRIL inhibition, which has shown rapid, deep, and sustained improvement in proteinuria with a favorable safety profile and patient-friendly monthly subcutaneous administration.
Inaxaplin Program Updates and Strategic Decisions
The pivotal Phase III AMPLITUDE study for inaxaplin in primary AMKD is on track for an interim analysis in early 2027, potentially leading to accelerated approval. The Phase IIb AMPLIFIED study, evaluating inaxaplin in AMKD patients with moderate proteinuria or type 2 diabetes, has completed enrollment with results expected in H2 2026. This strategic separation of patient populations was made early on to address their clear differences.
Type 1 Diabetes Program Resumption and Unprecedented Results
Dosing in the Phase I/II/III study for zimislecel in type 1 diabetes has resumed following a manufacturing analysis. Previous clinical results demonstrated unprecedented🌐 outcomes, with 10 out of 12 patients becoming insulin-free after a full dose and one year of follow-up, particularly noteworthy for patients with long-standing T1D, undetectable endogenous insulin production, and severe hypoglycemic events.
JOURNAVX Commercial Momentum and Payer Progress
JOURNAVX continues to build momentum with strong prescription growth, excellent physician and patient experiences, and expanding hospital and payer coverage. The field force has been doubled to 300 representatives, and a direct-to-patient telehealth platform (informed pain care) has been launched to enhance access. The company has secured coverage with two of the four major Medicare Part D plans, with a third close to agreement, positioning for gross-to-net normalization by year-end.
Renal Commercialization Preparations and Market Opportunity
Vertex is investing in the nephrology community for the long term, preparing for the commercial launch of Povetacicept in IgAN. The strategy focuses on Pove's differentiated efficacy, tolerability, and patient-centric administration, supported by a specialty-sized renal field force, broad reimbursement efforts, and robust patient support programs. The IgAN market alone represents approximately 160,000 patients in the U.S., with a significant unmet need for effective treatments.